ATRC Zgłoszenia SEC - AtriCure, Inc.- Raport roczny, oświadczenie o pełnomocnictwie, Prospekt

Podstawowe statystyki

CIK

1323885

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to AtriCure, Inc.

SEC Filings (Chronological Order)

Na tej stronie znajduje się pełna, chronologiczna lista zgłoszeń SEC, z wyłączeniem zgłoszeń własności, które udostępniamy gdzie indziej.

May 27, 2026	EX-1.01	AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2025 Exhibit 1.01 AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2025 This report for the year ended December 31, 2025 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosure requirements related to conflict miner
May 27, 2026	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. (Exact name of registrant as specified in charter) Delaware 000-51470 34-1940305 (State or other jurisdiction of incorporation) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC.
May 19, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2026 AtriCure, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2026 AtriCure, Inc.
May 19, 2026	EX-10.1	ATRICURE, INC. 2023 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF MAY 18, 2026) Exhibit 10.1 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF MAY 18, 2026) 1. Purpose. The purpose of the AtriCure, Inc. Amended and Restated 2023 Stock Incentive Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby directors, officers, employees, consultants and advisors (and prospective di
May 19, 2026	EX-10.2	ATRICURE, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN (AMENDED AND RESTATED AS OF MAY 18, 2026) Exhibit 10.2 ATRICURE, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN (AMENDED AND RESTATED AS OF MAY 18, 2026) 1. Purpose. The purposes of the Plan are as follows: a.To assist employees of the Company and its Participating Subsidiaries (as defined below) with the opportunity to acquire stock ownership interest in the Company. The Plan is intended to qualify as an “employee stock purchase plan” within the
May 6, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ¨ TRANSITION REPORT PURSUANT TO SE Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
May 6, 2026	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2026 AtriC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A Amendment No.
May 6, 2026	EX-99.1	AtriCure Reports First Quarter 2026 Financial Results Exhibit 99.1 For immediate release May 6, 2026 AtriCure Reports First Quarter 2026 Financial Results •First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year •First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million •U.S. revenue growth accelerated to 14.9%, driven by AtriClip FLEX-Mini®, cryoSPHERE® MAX™, E
May 6, 2026	EX-10.1	ATRICURE, INC. 2023 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Exhibit 10.1 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Summary of Performance Share Award Grant AtriCure, Inc., a Delaware corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the 2023 Stock Incentive Plan (as amended and restated from time to time, the “Plan”), and this Performance Share Award Agreement (the “Agreement”),
May 5, 2026	EX-99.1	AtriCure Reports First Quarter 2026 Financial Results Exhibit 99.1 For immediate release May 5, 2026 AtriCure Reports First Quarter 2026 Financial Results •First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year •First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million •U.S. revenue growth accelerated to 14.9%, driven by AtriClip FLEX-Mini®, cryoSPHERE® MAX™, E
May 5, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2026 AtriCure, Inc. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2026 AtriCure, Inc.
April 6, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 6, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
February 19, 2026	EX-21	SUBSIDIARIES OF ATRICURE, INC. Exhibit 21 SUBSIDIARIES OF ATRICURE, INC. AtriCure Europe, B.V., incorporated in the Netherlands AtriCure, LLC, a Delaware limited liability company SentreHEART LLC, a Delaware limited liability company AtriCure Spain, S.L., incorporated in Spain AtriCure Germany GmbH, incorporated in Germany AtriCure UK Limited, incorporated in the United Kingdom AtriCure Canada, Inc., incorporated in Canada Atri
February 19, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 AtriCure, Inc. (Exact name of registrant as specifi
February 19, 2026	EX-14	Code of Conduct Exhibit 14 \|\|\| ii Code of Conduct 1 Letter from Chief Executive Officer 2 The AtriCure Difference 3 Why We Have a Code 4 Our Responsibilities 5 Guidelines for Good Decisions 6 Putting Patients First 6 Meeting Our Commitment to Quality exhibit14-codeofconductf Code of Conduct Exhibit 14 \|\|\| ii Code of Conduct 1 Letter from Chief Executive Officer 2 The AtriCure Difference 3 Why We Have a Code 4 Our Responsibilities 5 Guidelines for Good Decisions 6 Putting Patients First 6 Meeting Our Commitment to Quality 7 Promoting with Integrity in the Marketplace 8 Using Social Media Responsibly 8 Marketing and Selling to Health Care Provid
February 17, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2026 AtriCure, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2026 AtriCure, Inc.
February 17, 2026	EX-99.1	AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results Exhibit 99.1 For immediate release February 17, 2026 AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results •Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year •Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million •Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over
January 12, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2026 AtriCure, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2026 AtriCure, Inc.
January 12, 2026	EX-99.1	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026 EX-99.1 Exhibit 99.1 For immediate release January 12, 2026 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026 MASON, Ohio, January 12, 2026 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management,
January 12, 2026	EX-10.1	FIRST AMENDMENT TO CREDIT AGREEMENT AND SECURITY AGREEMENT EX-10.1 Exhibit 10.1 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT AND SECURITY AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT AND SECURITY AGREEMENT (this “Amendment”), dated as of January 9, 2026, is among ATRICURE, INC. (the “Company”) and ATRICURE, LLC (together with the Company, the “Borrowers”), the other Loan Parties (if any) party hereto, the Lenders party hereto, the Issuing B
October 30, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ¨ TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
October 29, 2025	EX-99.1	AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025 Exhibit 99.1 For immediate release October 29, 2025 AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025 •Worldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) •Net loss of $0.3 million – an improvement of $7.6 million year over year •Adjusted EBITDA of $17.8 million – an increase of $9.9 million year over year •Gene
October 29, 2025	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A AMENDMENT NO. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A AMENDMENT NO.
October 29, 2025	EX-99.1	AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025 Exhibit 99.1 For immediate release October 29, 2025 AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025 •Worldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) •Net loss of $0.3 million – an improvement of $7.6 million year over year •Adjusted EBITDA of $17.8 million – an increase of $9.9 million year over year •Gene
October 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2025 AtriCure, Inc. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2025 AtriCure, Inc.
September 12, 2025	144	144 144 0001666600 XXXXXXXX LIVE 0001323885 AtriCure, Inc. 000-51470 7555 INNOVATION WAY MASON OH 45040 513-755-4100 Noznesky Justin J Officer COMMON RBC CAPITAL MARKETS LLC 250 NICOLLET MALL, SUITE 1700 MINNEAPOLIS MN 55401 3000 108891.00 49701415 09/12/2025 NASDAQ COMMON 03/01/2019 STOCK GRANT ISSUER N 1915 03/01/2019 N/A COMMON 03/01/2020 STOCK GRANT ISSUER N 1085 03/01/2020 N/A Y 09/12/2025 POA /
July 30, 2025	S-8	As filed with the Securities and Exchange Commission on July 30, 2025 S-8 As filed with the Securities and Exchange Commission on July 30, 2025 Registration No.
July 30, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ¨ TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
July 30, 2025	EX-FILING FEES	Filing Fee Table. Calculation of Filing Fee Tables S-8 AtriCure, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.001 per share Other 1,700,000 $ 30.60 $ 52,020,000.00 0.0001531 $ 7,965.00 Total Offering A
July 29, 2025	EX-99.1	AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025 Exhibit 99.1 For immediate release July 29, 2025 AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025 •Worldwide revenue of $136.1 million – an increase of 17.1% year over year (16.5% constant currency) •Net loss of $6.2 million – an improvement of $1.8 million year over year •Adjusted EBITDA of $15.4 million – an increase of $7.6 million year over year •Genera
July 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2025 AtriCure, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2025 AtriCure, Inc.
May 29, 2025	EX-1.01	Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2024 This report for the year ended December 31, 2024 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosure requirements related to conflict miner
May 29, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. (Exact name of registrant as specified in charter) Delaware 000-51470 (State or other jurisdiction of incorporation) (Commissio UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC.
May 20, 2025	EX-10.1	2023 Stock Incentive Plan (incorporated by reference to the Current Report on Form 8-K filed on May 20, 2025). Exhibit 10.1 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF MAY 19, 2025) 1. Purpose. The purpose of the AtriCure, Inc. Amended and Restated 2023 Stock Incentive Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby directors, officers, employees, consultants and advisors (and prospective di
May 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2025 AtriCure, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2025 AtriCure, Inc.
May 5, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
April 30, 2025	EX-10.1	Form of Performance Share Award Agreement for Awards Granted in 2025. Exhibit 10.1 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Summary of Performance Share Award Grant AtriCure, Inc., a Delaware corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the 2023 Stock Incentive Plan (as amended and restated from time to time, the “Plan”), and this Performance Share Award Agreement (the “Agreement”),
April 30, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ¨ TRANSITION REPORT PURSUANT TO SE Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
April 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2025 AtriCure, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2025 AtriCure, Inc.
April 29, 2025	EX-99.1	AtriCure Reports First Quarter 2025 Financial Results Exhibit 99.1 For immediate release April 29, 2025 AtriCure Reports First Quarter 2025 Financial Results •Worldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency) •Net loss of $6.7 million – an improvement of $6.5 million year over year •Adjusted EBITDA of $8.8 million – an increase of $6.0 million year over year MASON, Ohio, April 29, 2025 – AtriCure, Inc
April 7, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 7, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 26, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 26, 2025 AtriCure, Inc.
March 26, 2025	EX-99.1	Analyst and Investor Day Michael Carrel, CEO © 2025 AtriCure, Inc. All rights reserved. March 2025 Exhibit 99.1 © 2025 AtriCure, Inc. All rights reserved. 2 Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral stateme Analyst and Investor Day Michael Carrel, CEO © 2025 AtriCure, Inc. All rights reserved. March 2025 Exhibit 99.1 © 2025 AtriCure, Inc. All rights reserved. 2 Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature
February 14, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 AtriCure, Inc. (Exact name of registrant as specifi
February 14, 2025	EX-25.1	Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of U.S. Bank Trust Company, National Association, as Trustee under the Indenture EX-25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036
February 14, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ATRICURE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo
February 14, 2025	EX-10.18	Form of Indemnity Agreement with Directors and Executive Officers. Exhibit 10.18 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “AGREEMENT”) is made and effective as of this day of , 20 by and between ATRICURE, INC., a Delaware corporation (the “COMPANY”), and (“INDIVIDUAL”). RECITALS WHEREAS, Individual performs a valuable service to the Company in Individual’s capacity as a member of the Board of Directors of the Company; WHEREAS, the stockholders of the Co
February 14, 2025	EX-21	Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF ATRICURE, INC. AtriCure Europe, B.V., incorporated in the Netherlands AtriCure, LLC, a Delaware limited liability company SentreHEART LLC, a Delaware limited liability company AtriCure Spain, S.L., incorporated in Spain AtriCure Germany GmbH, incorporated in Germany AtriCure UK Limited, incorporated in the United Kingdom AtriCure Canada, Inc., incorporated in Canada Atri
February 14, 2025	S-3ASR	As filed with the Securities and Exchange Commission on February 14, 2025 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 14, 2025 Registration No.
February 14, 2025	EX-4.6	Form of Indenture EX-4.6 Exhibit 4.6 ATRICURE, INC. INDENTURE Dated as of [ ] U.S. Bank Trust Company, National Association, Trustee TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 5 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 Article 2 THE NOTES 6 Section 2.1 Issuable in
February 12, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2025 AtriCure, Inc.
February 12, 2025	EX-99.1	AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results Exhibit 99.1 For immediate release February 12, 2025 AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results •Fourth Quarter 2024 Worldwide revenue of $124.3 million – an increase of 16.6% year over year •Full Year 2024 Worldwide revenue of $465.3 million – an increase of 16.5% year over year •Launched cryoSPHERE®+, cryoSPHERE MAX™ and AtriClip® FLEX-Mini™ devices in the United S
January 13, 2025	EX-99.1	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day Exhibit 99.1 For immediate release January 13, 2025 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day MASON, Ohio, January 13, 2025 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) managemen
January 13, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 AtriCure, Inc.
January 13, 2025	EX-99.2	Creating a World Class Platform January 2025 © 2025 AtriCure, Inc. All rights reserved. J.P. MORGAN HEALTHCARE CONFERENCE Exhibit 99.2 Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection Creating a World Class Platform January 2025 © 2025 AtriCure, Inc. All rights reserved. J.P. MORGAN HEALTHCARE CONFERENCE Exhibit 99.2 Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature address matters that
November 14, 2024	SC 13G	ATRC / AtriCure, Inc. / Hood River Capital Management LLC Passive Investment SC 13G 1 o102246sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AtriCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu
October 30, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ¨ TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
October 29, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2024 AtriCure, Inc.
October 29, 2024	EX-99.1	AtriCure Reports Third Quarter 2024 Financial Results Exhibit 99.1 For immediate release October 29, 2024 AtriCure Reports Third Quarter 2024 Financial Results •Worldwide revenue of $115.9 million – an increase of 17.9% year over year •U.S. revenue of $95.5 million – an increase of 16.8% year over year •Achieved 20% growth on revenues from open appendage management devices in the U.S. •International revenue of $20.5 million – an increase of 23.3% yea
July 31, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ATRICURE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount to be Registered (1)(2) Proposed Maximum Offering Price Per Share (3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees t
July 31, 2024	S-8	As filed with the Securities and Exchange Commission on July 31, 2024 As filed with the Securities and Exchange Commission on July 31, 2024 Registration No.
July 31, 2024	EX-3.2	Amended and Restated Bylaws. july2024atricureamendeda Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ATRICURE, INC. (a Delaware corporation) i TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES ......................................................................................... 1 1.1 REGISTERED OFFICE. ........................................................................................ 1 1.2 OTHER OFFICES. ............
July 31, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ¨ TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
July 31, 2024	EX-3.3	Amended and Restated Bylaws (marked to show changes). comparisonresultjuly2024 Exhibit 3.3 FOURTH AMENDED AND RESTATED BYLAWS OF ATRICURE, INC. (a Delaware corporation) i TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES ......................................................................................... 1 1.1 REGISTERED OFFICE. ........................................................................................ 1 1.2 OTHER OFFICES. .....
July 30, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2024 AtriCure, Inc.
July 30, 2024	EX-99.1	AtriCure Reports Second Quarter 2024 Financial Results Exhibit 99.1 For immediate release July 30, 2024 AtriCure Reports Second Quarter 2024 Financial Results •Worldwide revenue of $116.3 million – an increase of 15.2% year over year •Positive cash flow generation of $8.1 million in second quarter 2024 MASON, Ohio, July 30, 2024 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), le
May 31, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. (Exact name of registrant as specified in charter) Delaware 000-51470 (State or other jurisdiction of incorporation) (Commissio UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC.
May 31, 2024	EX-1.01	Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2023 This report for the year ended December 31, 2023 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosure requirements related to conflict miner
May 14, 2024	EX-10.1	AtriCure, Inc. 2023 Stock Incentive Plan (Amended and Restated as of May 13, 2024). Exhibit 10.1 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF MAY 13, 2024) 1. Purpose. The purpose of the AtriCure, Inc. Amended and Restated 2023 Stock Incentive Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby directors, officers, employees, consultants and advisors (and prospective di
May 14, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2024 AtriCure, Inc.
May 14, 2024	EX-3.1	Restated Certificate of Incorporation. Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF ATRICURE, INC. (Originally incorporated on October 31, 2000) ARTICLE I The name of the corporation is AtriCure, Inc. (the “Corporation”). ARTICLE II The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, County of New Castle, City of Wilmington, DE 19801. The registered agent at this address is Nationa
May 2, 2024	EX-10.2	Form of Performance Stock Unit Award Agreement for Employees. Exhibit 10.2 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN PERFORMANCE STOCK UNIT AWARD AGREEMENT FOR EMPLOYEES ATRICURE, INC. (the “Company”), pursuant to the 2023 Stock Incentive Plan, as it may be amended from time to time (the “Plan”), hereby irrevocably grants you (the “Participant”), on March 1, 2024 (the “Grant Date”) a forfeitable Performance Stock Unit Award (the “Performance Unit Award”) repr
May 2, 2024	EX-10.1	Form of Performance Share Award Agreement for Awards Granted in 2024. Exhibit 10.1 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN PERFORMANCE STOCK AWARD AGREEMENT FOR EMPLOYEES ATRICURE, INC. (the “Company”), pursuant to the 2023 Stock Incentive Plan, as may be amended from time to time (the “Plan”), hereby irrevocably grants you (the “Participant”), on, 2024 (the “Grant Date”) a Performance Stock Award (the “Performance Stock Award”) of forfeitable shares of the Company
May 2, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ¨ TRANSITION REPORT PURSUANT TO SE Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
May 1, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2024 AtriCure, Inc.
May 1, 2024	EX-99.1	AtriCure Reports First Quarter 2024 Financial Results Exhibit 99.1 For immediate release May 1, 2024 AtriCure Reports First Quarter 2024 Financial Results •Worldwide revenue of $108.9 million – an increase of 16.4% year over year MASON, Ohio, May 1, 2024 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, to
April 23, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 23, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 3, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 3, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 20, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
February 27, 2024	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A Amendment No.
February 16, 2024	EX-10.24	Form of Restricted Share Unit Award Agreement under the Amended and Restated AtriCure, Inc. 2023 Stock Incentive Plan (incorporated by reference to our Annual Report on Form 10-K filed on February 16, 2024). Exhibit 10.24 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT FOR EMPLOYEES ATRICURE, INC. (the “Company”), pursuant to the 2023 Stock Incentive Plan, as it may be amended from time to time (the “Plan”), hereby irrevocably grants you (the “Participant”), on , 2023 (the “Grant Date”) a forfeitable Restricted Stock Unit Award (the “Restricted Unit Award”) representing
February 16, 2024	EX-19	Insider Trading Policy. Exhibit 19 ATRICURE, INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities Amended and restated effective as of March 1, 2023 Executive Summary Insider Trading – (a)It is a violation of US law for directors, officers, employees, and other individuals who possess material nonpublic information regarding the Company to execute transactions in Company Securitie
February 16, 2024	EX-21	Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF ATRICURE, INC. AtriCure Europe, B.V., incorporated in the Netherlands AtriCure, LLC, a Delaware limited liability company SentreHEART LLC, a Delaware limited liability company AtriCure Spain, S.L., incorporated in Spain AtriCure Germany GmbH, incorporated in Germany AtriCure UK Limited, incorporated in the United Kingdom AtriCure Canada, Inc., incorporated in Canada Atri
February 16, 2024	EX-97	Incentive Compensation Recoupment Policy. Exhibit 97 Incentive Compensation Recoupment Policy (the “Policy”) 1.Recoupment. If AtriCure, Inc. (the “Company”) is required to prepare a Restatement, the Company’s board of directors (the “Board”) shall, unless the Board’s Compensation Committee determines it to be Impracticable, take reasonably prompt action to recoup all Recoverable Compensation from any Covered Person. Subject to applicable
February 16, 2024	EX-10.22	Form of Performance Share Award Agreement for Awards Granted in 2023. Exhibit 10.22 ATRICURE, INC. 2014 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Summary of Performance Share Award Grant AtriCure, Inc., a Delaware corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the 2014 Stock Incentive Plan (as amended and restated from time to time, the “Plan”), and this Performance Share Award Agreement (the “Agreement”)
February 16, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 AtriCure, Inc. (Exact name of registrant as specifi
February 16, 2024	EX-10.23	Form of Restricted Stock Award Agreement under the Amended and Restated AtriCure, Inc. 2023 Stock Incentive Plan (incorporated by reference to our Annual Report on Form 10-K filed on February 16, 2024). Exhibit 10.23 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT FOR EMPLOYEES ATRICURE, INC. (the “Company”), pursuant to the 2023 Stock Incentive Plan, as may be amended from time to time (the “Plan”), hereby irrevocably grants you (the “Participant”), on , 2023 (the “Grant Date”) a Restricted Stock Award (the “Restricted Stock Award”) of forfeitable shares of the Company’
February 15, 2024	EX-99.1	AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results Exhibit 99.1 For immediate release February 15, 2024 AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results •Fourth Quarter 2023 Worldwide revenue of $106.5 million – an increase of 21.0% year over year •Full Year 2023 Worldwide revenue of $399.2 million – an increase of 20.8% year over year •Full Year 2023 U.S. revenue of $333.5 million – an increase of 20.3% year over year •Fu
February 15, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2024 AtriCure, Inc.
February 14, 2024	SC 13G/A	ATRC / AtriCure, Inc. / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 13, 2024	SC 13G/A	ATRC / AtriCure, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0363-atricureinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: AtriCure Inc Title of Class of Securities: Common Stock CUSIP Number: 04963C209 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule p
February 1, 2024	SC 13G/A	ATRC / AtriCure, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
January 25, 2024	SC 13G/A	ATRC / AtriCure, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us04963c2098012524.txt us04963c2098012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) ATRICURE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 04963C209 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de
January 8, 2024	EX-10.1	JPMorgan Credit Agreement, dated January 5, 2024 (incorporated by reference to our Current Report on Form 8-K filed on January 8, 2024). EX-10.1 Exhibit 10.1 Execution Version CREDIT AGREEMENT dated as of January 5, 2024 among ATRICURE, INC. and ATRICURE, LLC, as Borrowers, The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A. and SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY as Joint Lead Arrangers and Joint Bookrunners ASSET BASED LENDING TABLE OF CONTEN
January 8, 2024	EX-99.1	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024 EX-99.1 Exhibit 99.1 For immediate release January 8, 2024 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024 MASON, Ohio, January 8, 2024 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, ann
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2024 AtriCure, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2024 AtriCure, Inc.
January 4, 2024	EX-99.1	AtriCure Appoints Shlomi Nachman to the Board of Directors Exhibit 99.1 For immediate release January 4, 2024 AtriCure Appoints Shlomi Nachman to the Board of Directors MASON, Ohio, January 4, 2024—AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Direct
January 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2024 AtriCure, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2024 AtriCure, Inc.
December 8, 2023	SC 13G/A	ATRC / Atricure Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0015-atricureinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: AtriCure Inc Title of Class of Securities: Common Stock CUSIP Number: 04963C209 Date of Event Which Requires Filing of this Statement: November 30, 2023 Check the appropriate box to designate the rule p
November 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ¨ TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
November 1, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2023 AtriCure, Inc.
November 1, 2023	EX-99.1	AtriCure Reports Third Quarter 2023 Financial Results Exhibit 99.1 For immediate release November 1, 2023 AtriCure Reports Third Quarter 2023 Financial Results •Worldwide revenue of $98.3 million – an increase of 18.1% year over year •U.S. revenue of $81.7 million – an increase of 17.1% year over year •International revenue of $16.6 million – an increase of 23.2% year over year •Net loss of $9.1 million – an improvement of $3.2 million year over year
July 26, 2023	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ATRICURE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount to be Registered (1)(2) Proposed Maximum Offering Price Per Share (3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee
July 26, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ¨ TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
July 26, 2023	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ATRICURE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount to be Registered (1)(2) Proposed Maximum Offering Price Per Share (3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee
July 26, 2023	S-8	As filed with the Securities and Exchange Commission on July 26, 2023 As filed with the Securities and Exchange Commission on July 26, 2023 Registration No.
July 26, 2023	S-8	As filed with the Securities and Exchange Commission on July 26, 2023 S-8 As filed with the Securities and Exchange Commission on July 26, 2023 Registration No.
July 25, 2023	EX-99.1	AtriCure Reports Second Quarter 2023 Financial Results Exhibit 99.1 For immediate release July 25, 2023 AtriCure Reports Second Quarter 2023 Financial Results •Worldwide revenue of $100.9 million – an increase of 19.4% year over year •U.S. revenue of $84.9 million – an increase of 19.1% year over year •International revenue of $16.0 million – an increase of 20.7% year over year •Net loss of $5.1 million – an improvement of $9.7 million year over year
July 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2023 AtriCure, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2023 AtriCure, Inc.
May 26, 2023	EX-10.1	2023 Stock Incentive Plan (incorporated by reference to the Current Report on Form 8-K filed on May 14, 2024). Exhibit 10.1 ATRICURE, INC. 2023 STOCK INCENTIVE PLAN 1. Purpose. The purpose of the AtriCure, Inc. 2023 Stock Incentive Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby directors, officers, employees, consultants and advisors (and prospective directors, officers, employees, consultants and advisors) of the
May 26, 2023	EX-10.2	2018 Employee Stock Purchase Plan (Amended and Restated Effective May 25, 2023) (incorporated by reference to the Current Report on Form 8-K filed on May 26, 2023). Exhibit 10.2 ATRICURE, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN (AMENDED AND RESTATED EFFECTIVE MAY 25, 2023) 1. Purpose. The purposes of the Plan are as follows: a.To assist employees of the Company and its Participating Subsidiaries (as defined below) with the opportunity to acquire stock ownership interest in the Company. The Plan is intended to qualify as an “employee stock purchase plan” within
May 26, 2023	8-K	Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 25, 2023 AtriCure, Inc.
May 24, 2023	EX-1.01	Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD EX-1.01 2 formsd-exhibit101.htm EX-1.01 Exhibit 1.01 AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2022 This report for the year ended December 31, 2022 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosur
May 24, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. (Exact name of registrant as specified in charter) Delaware 000-51470 (State or other jurisdiction of incorporation) (Commissio UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC.
May 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ¨ TRANSITION REPORT PURSUANT TO SE Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
May 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2023 AtriCure, Inc. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2023 AtriCure, Inc.
May 2, 2023	EX-99.1	AtriCure Reports First Quarter 2023 Financial Results Exhibit 99.1 For immediate release May 2, 2023 AtriCure Reports First Quarter 2023 Financial Results •Worldwide revenue of $93.5 million – an increase of 25.4% year over year •U.S. revenue of $78.2 million – an increase of 25.6% year over year •International revenue of $15.3 million – an increase of 24.4% year over year •Net loss of $6.5 million – an improvement of $8.7 million year over year •Pos
April 10, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 10, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
February 22, 2023	EX-14	Code of Conduct atricurecodexofxconduct Code of Conduct Exhibit 14 From Our Chief Executive Officer and Chief Compliance Officer We are part of a truly remarkable organization.
February 22, 2023	EX-21	Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF ATRICURE, INC. AtriCure Europe, B.V., incorporated in the Netherlands AtriCure, LLC, a Delaware limited liability company SentreHEART LLC, a Delaware limited liability company AtriCure Spain, S.L., incorporated in Spain AtriCure Germany GmbH, incorporated in Germany AtriCure UK Limited, incorporated in the United Kingdom AtriCure Hong Kong Limited, incorporated in Hong K
February 22, 2023	EX-10.19	Form of Performance Share Award Agreement for Awards Granted in 2022 (incorporated by reference to our Annual Report on Form 10-K filed on February 22, 2023). Exhibit 10.19 ATRICURE, INC. 2014 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Summary of Performance Share Award Grant AtriCure, Inc., a Delaware corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the 2014 Stock Incentive Plan (as amended and restated from time to time, the “Plan”), and this Performance Share Award Agreement (the “Agreement”)
February 22, 2023	10-K	Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 AtriCure, Inc. (Exact name of registrant as specified i
February 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 AtriCure, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 AtriCure, Inc.
February 21, 2023	EX-99.1	AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results Exhibit 99.1 For immediate release February 21, 2023 AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results •2022 Worldwide revenue of $330.4 million – an increase of 20.4% year over year •2022 U.S. revenue of $277.2 million – an increase of 21.0% year over year •2022 International revenue of $53.2 million – an increase of 17.7% in 2022 MASON, Ohio, February 21, 2023 – AtriCure,
February 14, 2023	SC 13G/A	ATRC / AtriCure Inc. / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
February 14, 2023	SC 13G/A	ATRC / AtriCure Inc. / ALGER ASSOCIATES INC - ATRICURE, INC. Passive Investment SC 13G/A 1 d62536dsc13ga.htm ATRICURE, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* AtriCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 9, 2023	SC 13G/A	ATRC / AtriCure Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: AtriCure Inc. Title of Class of Securities: Common Stock CUSIP Number: 04963C209 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule
February 3, 2023	SC 13G/A	ATRC / AtriCure Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
February 3, 2023	SC 13G/A	ATRC / AtriCure Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us04963c2098020323.txt us04963c2098020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) ATRICURE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 04963C209 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de
January 9, 2023	EX-99.2	Creating a World Class Platform JANUARY 2023 © 2023 AtriCure, Inc. All rights reserved. J.P. MORGAN HEALTHCARE CONFERENCE Exhibit 99.2 Forward Looking Statements This presentation and oral statements made in connection with this presentation contain Creating a World Class Platform JANUARY 2023 © 2023 AtriCure, Inc. All rights reserved. J.P. MORGAN HEALTHCARE CONFERENCE Exhibit 99.2 Forward Looking Statements This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. Forward-looking s
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2023 AtriCure, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2023 AtriCure, Inc.
January 9, 2023	EX-99.1	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023 EX-99.1 2 atrc-20230109xexx991.htm EX-99.1 Exhibit 99.1 For immediate release January 9, 2023 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023 MASON, Ohio, January 9, 2023 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and
November 2, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ¨ TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
November 1, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2022 AtriCure, Inc.
November 1, 2022	EX-99.1	AtriCure Reports Third Quarter 2022 Financial Results Exhibit 99.1 For immediate release November 1, 2022 AtriCure Reports Third Quarter 2022 Financial Results MASON, Ohio, November 1, 2022 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2022 financial results. ?We are proud
August 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ¨ TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
August 3, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ATRICURE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount to be Registered (1)(2) Proposed Maximum Offering Price Per Share (3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid
August 3, 2022	S-8	As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No.
August 2, 2022	EX-99.1	AtriCure Reports Second Quarter 2022 Financial Results Exhibit 99.1 For immediate release August 2, 2022 AtriCure Reports Second Quarter 2022 Financial Results MASON, Ohio, August 2, 2022 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results. “We delivered a
August 2, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2022 AtriCure, Inc.
August 2, 2022	EX-99.2	Creating a World Class Afib Platform AUGUST 2022 © 2022 AtriCure, Inc. All rights reserved. INVESTOR PRESENTATION Exhibit 99.2 Forward Looking Statements This presentation and oral statements made in connection with this presentation contain “forward Creating a World Class Afib Platform AUGUST 2022 © 2022 AtriCure, Inc. All rights reserved. INVESTOR PRESENTATION Exhibit 99.2 Forward Looking Statements This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statement
May 31, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. (Exact name of registrant as specified in charter) SD 1 atrc-formsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. (Exact name of registrant as specified in charter) Delaware 000-51470 34-1940305 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 7555 Innovation Way Mason, OH 45040 (Address of principal executiv
May 31, 2022	EX-1.01	Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2021 This report for the year ended December 31, 2021 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosure requirements related to conflict miner
May 27, 2022	EX-10.1	AtriCure, Inc. 2014 Stock Incentive Plan (Amended and Restated as of May 25, 2022) (incorporated by reference to our Current Report on Form 8-K filed on May 27, 2022). Exhibit 10.1 ATRICURE, INC. 2014 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF MAY 25, 2022) TABLE OF CONTENTS 1 Purposes 1 2 Definitions 1 3 Administration of the Plan 3 (a) Authority of Committee 3 (b) Binding Authority 4 (c) Delegation of Authority 4 4 Eligibility 4 5 Common Shares Subject to the Plan 4 (a) Authorized Number of Common Shares 4 (b) Share Counting 4 (c) Award Limitations. 5 (d
May 27, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 25, 2022 AtriCure, Inc.
May 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ¨ TRANSITION REPORT PURSUANT TO SE Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
May 3, 2022	EX-99.1	AtriCure Reports First Quarter 2022 Financial Results Exhibit 99.1 For immediate release May 3, 2022 AtriCure Reports First Quarter 2022 Financial Results MASON, Ohio, May 3, 2022 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results. ?Our team delivered exc
May 3, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2022 AtriCure, Inc.
May 3, 2022	EX-99.2	© 2022 AtriCure, Inc. All rights reserved. AtriCure Investor Presentation Creating a World Class Afib Platform Exhibit 99.2 This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which ar ? 2022 AtriCure, Inc. All rights reserved. AtriCure Investor Presentation Creating a World Class Afib Platform Exhibit 99.2 This presentation and oral statements made in connection with this presentation contain ?forward-looking statements,? which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statements address, among other things,
April 13, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2022 AtriCure, Inc.
April 13, 2022	EX-99.1	AtriCure Launches EnCompass® Clamp, a part of Isolator Synergy™ Ablation System New clamp is designed to improve efficiency of concomitant ablation procedures Exhibit 99.1 For immediate release April 12, 2022 AtriCure Launches EnCompass? Clamp, a part of Isolator Synergy? Ablation System New clamp is designed to improve efficiency of concomitant ablation procedures MASON, Ohio ? (BUSINESS WIRE) ? April 12, 2022 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage
April 11, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A 1 atrc-defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi
April 11, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 atrc-def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permit
February 17, 2022	EX-25.1	Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of U.S. Bank National Association, as Trustee under the Indenture EX-25.1 5 d281828dex251.htm EX-25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified i
February 17, 2022	EX-21	Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF ATRICURE, INC. AtriCure Europe, B.V., incorporated in the Netherlands AtriCure, LLC, a Delaware limited liability company Endoscopic Technologies, LLC, a Delaware limited liability company nContact Surgical LLC, a Delaware limited liability company SentreHEART LLC, a Delaware limited liability company AtriCure Spain, S.L., incorporated in Spain AtriCure Germany GmbH, inc
February 17, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 AtriCure, Inc. (Exact name of registrant as specified i
February 17, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ATRICURE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo
February 17, 2022	S-3ASR	As filed with the Securities and Exchange Commission on February 17, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 17, 2022 Registration No.
February 17, 2022	EX-10.20	AtriCure, Inc. Executive Leadership Severance Policy (incorporated by referenced to our Annual Report on Form 10-K filed on February 17, 2022). Exhibit 10.21 ATRICURE, INC. EXECUTIVE LEADERSHIP SEVERANCE POLICY 1. Purpose The purpose of the AtriCure, Inc. Executive Leadership Severance Policy (the ?Policy?) is to provide payments to eligible executive officers of AtriCure, Inc. (the ?Company?), other than the Chief Executive Officer, whose employment is involuntarily terminated in certain circumstances not involving a change in control of
February 17, 2022	EX-4.6	Form of Indenture Exhibit 4.6 ATRICURE, INC. INDENTURE Dated as of [ ] U.S. Bank National Association, Trustee TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 5 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 Article 2 THE NOTES 6 Section 2.1 Issuable in Series 6 Section 2.2 Esta
February 17, 2022	EX-14	Code of Conduct. Code of Conduct Introduction from Our Chief Executive Officer and Chief Compliance Officer Team AtriCure, We are a part of a truly remarkable organization, and now we must fulfill the legacy started by those who came before us.
February 15, 2022	EX-99.1	AtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results Exhibit 99.1 For immediate release February 15, 2022 AtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results MASON, Ohio, February 15, 2022 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2021 and full
February 15, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2022 AtriCure, Inc.
February 14, 2022	SC 13G	ATRC / AtriCure Inc. / ALLIANCEBERNSTEIN L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 14, 2022	SC 13G/A	ATRC / AtriCure Inc. / ALGER ASSOCIATES INC - ATRICURE, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AtriCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
February 14, 2022	SC 13G/A	ATRC / AtriCure Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) AtriCure, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 04963C209 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is fi
February 9, 2022	SC 13G/A	ATRC / AtriCure Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
February 9, 2022	SC 13G/A	ATRC / AtriCure Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: AtriCure Inc. Title of Class of Securities: Common Stock CUSIP Number: 04963C209 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule
February 3, 2022	SC 13G/A	ATRC / AtriCure Inc. / BlackRock Inc. Passive Investment us04963c2098020222.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) ATRICURE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 04963C209 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 10, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2022 AtriCure, Inc.
January 10, 2022	EX-99.2	© 2022 AtriCure, Inc. All rights reserved. AtriCure Investor Presentation Creating a World Class Afib Platform This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements ? 2022 AtriCure, Inc. All rights reserved. AtriCure Investor Presentation Creating a World Class Afib Platform This presentation and oral statements made in connection with this presentation contain ?forward-looking statements,? which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statements address, among other things, AtriCure?s e
January 10, 2022	EX-99.1	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022 Exhibit 99.1 For immediate release January 10, 2022 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022 MASON, Ohio, January 10, 2022 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announce
November 4, 2021	EX-10.1	AtriCure, Inc. 2018 Employee Stock Purchase Plan (Amended and Restated effective January 1, 2022 (incorporated by reference to our Quarterly Report on Form 10-Q, filed on November 4, 2021). Exhibit 10.1 ATRICURE, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2022 1.Purpose. The purposes of the Plan are as follows: (a)To assist employees of the Company and its Participating Subsidiaries (as defined below) with the opportunity to acquire stock ownership interest in the Company. The Plan is intended to qualify as an ?employee stock purchase plan? withi
November 4, 2021	EX-10.2	Sixth Amendment to Loan and Security Agreement dated November 1, 2021 among AtriCure, Inc., Silicon Valley Bank and other parties named therein (incorporated by reference to our Quarterly Report on Form 10-Q filed on November 4, 2021). Exhibit 10.2 SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Sixth Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 1st day of November, 2021, among (a) SILICON VALLEY BANK, a California corporation (?SVB?), in its capacity as Administrative Agent (?Agent?), (b) SVB, and each other lender and other financial institutions party to the Loan Agreement (as defined b
November 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ¨ TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
November 3, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2021 AtriCure, Inc.
November 3, 2021	EX-99.1	AtriCure Reports Third Quarter 2021 Financial Results Exhibit 99.1 For immediate release November 3, 2021 AtriCure Reports Third Quarter 2021 Financial Results MASON, Ohio, November 3, 2021 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2021 financial results. ?Our results were driven by strong growth across key product lines,
August 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ¨TRANSITION REPORT PURSUANT TO SECTI hibi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
August 4, 2021	EX-99.1	AtriCure Reports Second Quarter 2021 Financial Results Exhibit 99.1 For immediate release August 4, 2021 ? AtriCure Reports Second Quarter 2021 Financial Results MASON, Ohio, August 4, 2021 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results. ? ?Our second quarter results were driven by outperformance across o
August 4, 2021	EX-99.2	AtriCure Investor Presentation Creating a World Class Afib Platform © 2021 AtriCure, Inc. All rights reserved. AtriCure 1 Forward Looking Statements This presentation contains “forward-looking statements,” which are statements related to future eve Exhibit 99.2 ? AtriCure Investor Presentation Creating a World Class Afib Platform ? 2021 AtriCure, Inc. All rights reserved. AtriCure 1 ? Forward Looking Statements This presentation contains ?forward-looking statements,? which are statements related to future events that by their nature address matters that are uncertain. All forward-looking information is inherently uncertain and actual results
August 4, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2021 AtriCure, Inc.
June 15, 2021	EX-99.1	AtriCure Names Two New Members to the Board of Directors Exhibit 99.1 For immediate release June 15, 2021 ? ? AtriCure Names Two New Members to the Board of Directors ? MASON, Ohio ? (BUSINESS WIRE) ? June 15, 2021? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors. ?
June 15, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2021 AtriCure, Inc.
May 28, 2021	EX-1.01	Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 ? AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2020 ? This report for the year ended December 31, 2020 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosure requirements related to conflict m
May 28, 2021	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. (Exact name of registrant as specified in charter) ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ? ATRICURE, INC.
May 24, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2021 AtriCure, Inc.
April 29, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2021 AtriCure, Inc.
April 29, 2021	EX-99.1	AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients FDA approval results in the only label of its kind for more than 3 million patients in the United States, significantly expanding AtriCure’s addressab Exhibit 99.1 For immediate release April 29, 2021 ? AtriCure?s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients ? FDA approval results in the only label of its kind for more than 3 million patients in the United States, significantly expanding AtriCure?s addressable market Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% diff
April 28, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
April 27, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2021 AtriCure, Inc.
April 27, 2021	EX-99.1	AtriCure Reports First Quarter 2021 Financial Results Exhibit 99.1 For immediate release April 27, 2021 ? AtriCure Reports First Quarter 2021 Financial Results MASON, Ohio, April 27, 2021 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2021 financial results. ? ?Our growth in the first quarter is a testament of our team?s strong
April 8, 2021	EX-99.1	AtriCure Names B. Kristine Johnson Board Chair Exhibit 99.1 For immediate release April 8, 2021 AtriCure Names B. Kristine Johnson Board Chair MASON, Ohio – (BUSINESS WIRE) – April 8, 2021– AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair. In addition, the Company announced
April 8, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 8, 2021 AtriCure, Inc.
April 8, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 8, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
February 26, 2021	EX-10.20	Form of Performance Share Award Agreement for Awards Granted in 2021 (incorporated by reference to our Annual Report on Form 10-K filed on February 26, 2021). EX-10.20 4 atrc-20201231xex1020.htm EX-10.20 Exhibit 10.20 ATRICURE, INC. 2014 STOCK INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Summary of Performance Share Award Grant AtriCure, Inc., a Delaware corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the 2014 Stock Incentive Plan (as amended and restated from time to time, the “Plan”), and this
February 26, 2021	EX-21	Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF ATRICURE, INC. AtriCure Europe, B.V., incorporated in the Netherlands AtriCure, LLC, a Delaware limited liability company Endoscopic Technologies, LLC, a Delaware limited liability company nContact Surgical LLC, a Delaware limited liability company SentreHEART LLC, a Delaware limited liability company AtriCure Spain, S.L., incorporated in Spain AtriCure Germany GmbH, inc
February 26, 2021	EX-10.19	Form of First Amendment to Performance Share Award Agreement for Awards Granted in 2019 and 2020. EX-10.19 3 atrc-20201231xex1019.htm EX-10.19 Exhibit 10.19 ATRICURE, INC. 2014 STOCK INCENTIVE PLAN FIRST AMENDMENT TO PERFORMANCE SHARE AWARD AGREEMENT This First Amendment to Performance Share Award Agreement (the "Amendment") is effective as of February 25, 2021 and is entered into by and between AtriCure, Inc., a Delaware corporation (the "Company") and [] (the "Grantee"). WHEREAS, the C
February 26, 2021	EX-10.17	Fifth Amendment to Loan and Security Agreement dated February 8, 2021 among AtriCure, Inc., Silicon Valley Bank and the other parties named therein (incorporated by reference to our Annual Report on Form 10-K filed on February 26, 2021). Exhibit 10.17 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED [***] ? FIFTH AMENDMENT to Loan and security agreement ? This Fifth Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 8th day of February, 2021, among (a) SILICON VALLEY BANK, a Cal
February 26, 2021	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 AtriCure, Inc. (Exact name of registrant as specifi
February 23, 2021	EX-99.1	AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results Exhibit 99.1 For immediate release February 23, 2021 ? AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results MASON, Ohio, February 23, 2021 ? AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2020 and full year 2020 financial results. ? ?Despite challenges po
February 23, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2021 AtriCure, Inc.
February 16, 2021	SC 13G	SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) AtriCure, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 04963C209 (CUSIP NUMBER) December 31, 2020 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is fil
February 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AtriCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) December 31, 2 AtriCure, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AtriCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 16, 2021	SC 13G	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AtriCure Inc (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 16, 2021	EX-99	JOINT FILING AGREEMENT Invesco Joint Filing Agreement JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd.
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: AtriCure Inc. Title of Class of Securities: Common Stock CUSIP Number: 04963C209 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule
January 29, 2021	SC 13G/A	SC 13G/A us04963c2098012821.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) ATRICURE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 04963C209 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 11, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2021 ATRICURE, INC.
January 11, 2021	EX-99.1	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020 Fourth quarter 2020 worldwide revenue of $57.7 million (U.S. $47.4 million, International $10.3 million) Exhibit 99.1 For immediate release January 11, 2021 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020 Fourth quarter 2020 worldwide revenue of $57.7 million (U.S. $47.4 million, International $10.3 million) MASON, Ohio, January 11, 2021 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) ma
January 11, 2021	EX-99.2	AtriCure Investor Presentation Creating a World Class Afib Platform January 2021 © 2021 AtriCure, Inc. All rights reserved. AtriCure 1 Forward Looking Statements This presentation contains “forward-looking statements,” which are statements related EX-99.2 3 atrc-20210111xex992.htm EX-99.2 Exhibit 99.2 AtriCure Investor Presentation Creating a World Class Afib Platform January 2021 © 2021 AtriCure, Inc. All rights reserved. AtriCure 1 Forward Looking Statements This presentation contains “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. All forward-looking
December 10, 2020	SC 13G/A	ATRC / AtriCure, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 8 ATRICURE INC COMMON STOCK Cusip #04963C209 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #04963C209 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 723,594 Item 6: 0 Item 7: 1,849,182 Item 8: 0 Item 9: 1,849,182 Item 11: 4.107% Ite
November 6, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
November 5, 2020	EX-99.2	This presentation contains “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. All forward-looking information is inherently uncertain and actual results may differ mate EX-99.2 AtriCure Investor Presentation Creating a World Class Afib Platform November 2020 © 2020 AtriCure, Inc. All rights reserved. Exhibit 99.2 This presentation contains “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. All forward-looking information is inherently uncertain and actual results may differ material
November 5, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2020 AtriCure, Inc.
November 5, 2020	EX-99.1	AtriCure Reports Third Quarter 2020 Financial Results EX-99.1 Exhibit 99.1 For immediate release November 5, 2020 AtriCure Reports Third Quarter 2020 Financial Results • Worldwide revenue of $54.8 million – a decrease of 3.3% year over year • U.S. revenue of $44.7 million – a decrease of 3.1% year over year • International revenue of $10.1 million – a decrease of 4.1% year over year MASON, Ohio, November 5, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a lea
August 10, 2020	SC 13G/A	ATRC / AtriCure, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9 )* AtriCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04963C209 (CUSIP Number) July 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
August 6, 2020	EX-10.1	Offer Letter, dated August 6, 2020, by and between AtriCure, Inc. and Angela L. Wirick EX-10.1 2 d941955dex101.htm EX-10.1 Exhibit 10.1 7555 Innovation Way Mason, OH 45040 United States 513-755-4100 August 4, 2020 Angela Wirick Dear Angie, I am pleased to formally extend this offer to you for your promotion to the position of Chief Financial Officer. This letter will confirm the details of the offer. This formal offer will remain open until the close of business on August 6, 2020. P
August 6, 2020	EX-99.1	AtriCure Announces Angie Wirick as Chief Financial Officer EX-99.1 3 d941955dex991.htm EX-99.1 Exhibit 99.1 For immediate release August 6, 2020 AtriCure Announces Angie Wirick as Chief Financial Officer MASON, Ohio, August 6, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial
August 6, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2020 ATRICURE, INC.
July 30, 2020	S-8	- FORM S-8 S-8 1 d757929ds8.htm FORM S-8 As filed with the Securities and Exchange Commission on July 30, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATRICURE, INC. (Exact name of Registrant as Specified in its Charter) Delaware 34-1940305 (State Or Other Jurisdiction Of Incorporation Or Or
July 29, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
July 28, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2020 AtriCure, Inc.
July 28, 2020	EX-99.1	AtriCure Reports Second Quarter 2020 Financial Results Exhibit 99.1 For immediate release July 28, 2020 AtriCure Reports Second Quarter 2020 Financial Results · Worldwide revenue of $40.8 million – a decrease of 30.7% year over year · U.S. revenue of $33.7 million – a decrease of 28.6% year over year · International revenue of $7.1 million – a decrease of 39.0% year over year MASON, Ohio, July 28, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a leading in
June 10, 2020	SC 13G/A	ATRC / AtriCure, Inc. / FMR LLC / Fidelity Passive Investment SCHEDULE 13G Amendment No. 7 ATRICURE INC COMMON STOCK Cusip #04963C209 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #04963C209 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 938,677 Item 6: 0 Item 7: 4,934,219 Item 8: 0 Item 9: 4,934,219 Item 11: 11.200% It
May 28, 2020	SD	- FORM SD SD 1 atrc-20200528corresp.htm FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD Specialized Disclosure Report ATRICURE, INC. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 000-51470 (Commission File Number) 34-1940305 (IRS Employer Identification No.) 7555 Innovation Way Mason, OH (Address
May 28, 2020	EX-1.01	Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 AtriCure, Inc. Conflict Minerals Report For the Year Ended December 31, 2019 This report for the year ended December 31, 2019 (the Reporting Period) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). The Rule was adopted by the Securities and Exchange Commission (SEC) to implement reporting and disclosure requirements related to conflict m
May 22, 2020	EX-10.1	AtriCure, Inc. 2014 Stock Incentive Plan (Amended and Restated as of May 20, 2020) (incorporated by reference to our Current Report on Form 8-K, filed on May 22, 2020). ATRICURE, INC. 2014 STOCK INCENTIVE PLAN (AMENDED AND RESTATED AS OF MAY 20, 2020) TABLE OF CONTENTS 1 Purpose 1 2 Definitions 1 3 Administration of the Plan 4 (a) Authority of Committee 4 (b) Binding Authority 5 (c) Delegation of Authority 5 4 Eligibility 6 5 Common Shares Subject to the Plan 6 (a) Authorized Number of Common Shares 6 (b) Share Counting 6 (c) Award Limitations.
May 22, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2020 ATRICURE, INC.
May 13, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2020 AtriCure, Inc.
May 13, 2020	EX-99.1	AtriCure Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 AtriCure Announces Proposed Public Offering of Common Stock MASON, Ohio—(BUSINESS WIRE)—May 11, 2020— AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sell approximately $100 million
May 13, 2020	EX-1.1	Underwriting Agreement dated as of May 11, 2020, among AtriCure, Inc. and J.P. Morgan Securities LLC and Piper Sandler & Co., as representatives of the underwriters named therein. EX-1.1 Exhibit 1.1 Execution Version ATRICURE, INC. 3,977,273 Shares of Common Stock Underwriting Agreement May 11, 2020 J.P. Morgan Securities LLC Piper Sandler & Co. as Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Piper Sandler & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and
May 13, 2020	424B5	Title of Each Class of Securities to be Registered 424B5 1 d853725d424b5.htm 424B5 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, par value $0.001 per share $201,249,972 $26,122.25 (1) Assumes exercise in full of the underwriters’ option to purchase additional shares of common stock. (2) Calculated in accor
May 13, 2020	EX-99.2	AtriCure Announces Pricing of Public Offering of Common Stock EX-99.2 Exhibit 99.2 AtriCure Announces Pricing of Public Offering of Common Stock MASON, Ohio—(BUSINESS WIRE)—May 11, 2020 — AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to the public of $44.00 pe
May 11, 2020	424B5	Joint Book-Running Managers J.P. Morgan Piper Sandler Canaccord Genuity Needham & Company Stifel SVB Leerink BTIG 424B5 1 d853725d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-230001 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supp
May 8, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2020 AtriCure, Inc.
May 8, 2020	EX-99.1	AtriCure Announces Results from CONVERGE IDE Clinical Trial Results presented virtually via Heart Rhythm 365 Platform; shows primary effectiveness superiority in favor of the hybrid Convergent procedure Exhibit 99.1 For immediate release May 8, 2020 AtriCure Announces Results from CONVERGE IDE Clinical Trial Results presented virtually via Heart Rhythm 365 Platform; shows primary effectiveness superiority in favor of the hybrid Convergent procedure MASON, Ohio – (BUSINESS WIRE) – May 8, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and
April 30, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 000-51470 AtriCure, Inc.
April 29, 2020	EX-10.1	Fourth Amendment to Loan and Security Agreement dated April 29, 2020 among AtriCure, Inc., Silicon Valley Bank and the other parties named therein (incorporated by reference to our Current Report on Form 8-K filed with the Commission on April 29, 2020) Exhibit 10.1 FOURTH AMENDMENT to Loan and security agreement This Fourth Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 29th day of April, 2020, among (a) SILICON VALLEY BANK, a California corporation (“SVB”), in its capacity as Administrative Agent (“Agent”), (b) SVB, and each other lender and other financial institutions party to the Loan Agreement (as defin
April 29, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2020 AtriCure, Inc.
April 29, 2020	EX-99.2	AtriCure Investor Presentation Creating a World Class Afib Platform April 2020 1 © 2020 AtriCure, Inc. All rights reserved. AtriCure Forward Looking Statements This presentation contains “forward-looking statements,” which are statements related to Exhibit 99.2 AtriCure Investor Presentation Creating a World Class Afib Platform April 2020 1 © 2020 AtriCure, Inc. All rights reserved. AtriCure Forward Looking Statements This presentation contains “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. All forward-looking information is inherently uncertain and act
April 29, 2020	EX-99.1	AtriCure Reports First Quarter 2020 Financial Results Exhibit 99.1 For immediate release April 29, 2020 AtriCure Reports First Quarter 2020 Financial Results · Worldwide revenue of $53.2 million – a decrease of 1.4% year over year · U.S. revenue of $43.5 million – an increase of 1.1% year over year · International revenue of $9.8 million – a decrease of 11.0% year over year MASON, Ohio, April 29, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a leading in
April 13, 2020	EX-99.1	AtriCure Announces CONVERGE IDE Trial Results Accepted for Late-Breaking Clinical Trial Sessions at Annual Heart Rhythm Society (HRS) Meeting Exhibit 99.1 For immediate release April 13, 2020 AtriCure Announces CONVERGE IDE Trial Results Accepted for Late-Breaking Clinical Trial Sessions at Annual Heart Rhythm Society (HRS) Meeting MASON, Ohio — April 13, 2020 — AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from
April 13, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 13, 2020 AtriCure, Inc.
April 10, 2020	SC 13G/A	ATRC / AtriCure, Inc. / FMR LLC / Fidelity Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 6 ATRICURE INC COMMON STOCK Cusip #04963C209 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #04963C209 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 257,139 Item 6: 0 Item 7: 3,542,339 Item 8: 0 Item 9: 3,542,3

ATRC / AtriCure, Inc. - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

Podstawowe statystyki

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings